Ascletis Pharma Inc. (1672.HK)

HKD 6.55

(3.15%)

Operating Income Summary of Ascletis Pharma Inc.

Ascletis Pharma Inc.'s latest annual operating income in 2023 was -306.81 Million CNY , down -17.55% from previous year.
Ascletis Pharma Inc.'s latest quarterly operating income in 2024 Q2 was -86.86 Million CNY , down 0.0% from previous quarter.
Ascletis Pharma Inc. reported an annual operating income of -262.81 Million CNY in 2022, down -34.16% from previous year.
Ascletis Pharma Inc. reported an annual operating income of -195.89 Million CNY in 2021, down -25.23% from previous year.
Ascletis Pharma Inc. reported a quarterly operating income of -86.86 Million CNY for 2024 Q2, down 0.0% from previous quarter.
Ascletis Pharma Inc. reported a quarterly operating income of -40.41 Million CNY for 2023 Q1, up 63.87% from previous quarter.

Annual Operating Income Chart of Ascletis Pharma Inc. (2023 - 2016)

Historical Annual Operating Income of Ascletis Pharma Inc. (2023 - 2016)

Year	Operating Income	Operating Income Growth
2023	-306.81 Million CNY	-17.55%
2022	-262.81 Million CNY	-34.16%
2021	-195.89 Million CNY	-25.23%
2020	-156.42 Million CNY	-329.28%
2019	-36.44 Million CNY	40.17%
2018	-60.91 Million CNY	9.34%
2017	-67.18 Million CNY	-57.16%
2016	-42.75 Million CNY	0.0%

Year	Operating Income	Operating Income Growth
2024 Q1	-86.86 Million CNY	23.29%
2024 Q2	-86.86 Million CNY	0.0%
2023 Q1	-40.41 Million CNY	63.87%
2023 FY	-308.94 Million CNY	-17.55%
2023 Q4	-113.24 Million CNY	0.72%
2023 Q3	-114.05 Million CNY	-182.21%
2023 Q2	-40.41 Million CNY	0.0%
2022 FY	-262.81 Million CNY	-34.16%
2022 Q4	-111.86 Million CNY	0.0%
2022 Q3	-111.86 Million CNY	-79.14%
2022 Q2	-62.44 Million CNY	0.0%
2022 Q1	-62.44 Million CNY	-4.64%
2021 Q3	-59.67 Million CNY	-7.41%
2021 Q2	-55.55 Million CNY	0.0%
2021 FY	-195.89 Million CNY	-25.23%
2021 Q4	-59.67 Million CNY	0.0%
2021 Q1	-55.55 Million CNY	27.58%
2020 Q4	-76.71 Million CNY	0.0%
2020 Q3	-76.71 Million CNY	-60.68%
2020 Q2	-47.74 Million CNY	0.0%
2020 Q1	-47.74 Million CNY	15.58%
2020 FY	-156.42 Million CNY	-329.28%
2019 Q3	-56.55 Million CNY	-17.39%
2019 FY	-36.44 Million CNY	40.17%
2019 Q4	-56.55 Million CNY	0.0%
2019 Q1	-48.17 Million CNY	33.98%
2019 Q2	-48.17 Million CNY	0.0%
2018 Q2	9.16 Million CNY	-37.18%
2018 Q3	-72.97 Million CNY	-896.18%
2018 Q4	-72.97 Million CNY	0.0%
2018 FY	-60.91 Million CNY	9.34%
2018 Q1	14.59 Million CNY	139.4%
2017 Q1	-1.81 Million CNY	0.0%
2017 FY	-67.18 Million CNY	-57.16%
2017 Q2	-18.56 Million CNY	-920.62%
2017 Q4	-37.03 Million CNY	0.0%
2017 Q3	-37.03 Million CNY	-99.46%
2016 FY	-42.75 Million CNY	0.0%

Peer Operating Income Comparison of Ascletis Pharma Inc.

Name	Operating Income	Operating Income Difference
Uni-Bio Science Group Limited	67.76 Million HKD	552.737%
CK Life Sciences Int'l., (Holdings) Inc.	897.95 Million HKD	134.168%